

Meg J Jardine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2471302/publications.pdf>

Version: 2024-02-01

186
papers

14,958
citations

31902

53
h-index

19690

117
g-index

200
all docs

200
docs citations

200
times ranked

14634
citing authors

#	ARTICLE	IF	CITATIONS
1	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	13.9	3,760
2	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1813-1821.	3.0	787
3	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet</i> , The, 2017, 390, 1888-1917.	6.3	662
4	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 845-854.	5.5	595
5	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
6	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet</i> , The, 2009, 373, 1009-1015.	6.3	384
7	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	3.8	376
8	Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2010, 153, 23.	2.0	297
9	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 368-375.	3.0	280
10	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	2.6	260
11	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
12	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018, 138, 1537-1550.	1.6	200
13	Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 852-858.	3.0	194
14	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	1.4	194
15	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1237-1250.	2.2	190
16	The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2008, 5, e207.	3.9	189
17	Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2012, 156, 445.	2.0	179
18	Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 956-965.	1.2	171

#	ARTICLE	IF	CITATIONS
19	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2888-2899.	1.2	171
20	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e014908.	1.6	161
21	Systematic Review: Sodium Bicarbonate Treatment Regimens for the Prevention of Contrast-Induced Nephropathy. <i>Annals of Internal Medicine</i> , 2009, 151, 631.	2.0	156
22	Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013, 34, 1807-1817.	1.0	156
23	Effects of Fibrates in Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2061-2071.	1.2	148
24	Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0159252.	1.1	145
25	Proteinuria and Stroke: A Meta-analysis of Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2009, 53, 417-425.	2.1	128
26	Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2012, 60, 770-778.	2.1	110
27	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 181.	2.0	108
28	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
29	Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2014, 63, 968-978.	2.1	105
30	Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation. <i>Kidney International</i> , 2009, 76, 659-664.	2.6	103
31	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	3.8	103
32	Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2766-2772.	3.0	97
33	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c $\leq 7\%$. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
34	Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 110-119.	2.2	93
35	Survival outcomes of supportive care versus dialysis therapies for elderly patients with end-stage kidney disease: A systematic review and meta-analysis. <i>Nephrology</i> , 2016, 21, 241-253.	0.7	93
36	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2229-2242.	3.0	93

#	ARTICLE	IF	CITATIONS
37	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	2.6	93
38	Effects of Canagliflozin in Patients with Baseline eGFR ≤ 30 ml/min per 1.73 m ² . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
39	Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2019, 73, 332-343.	2.1	84
40	The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 344, e3533-e3533.	3.0	83
41	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2925-2936.	3.0	82
42	Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 112-122.	2.1	81
43	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
44	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80
45	Survival of elderly dialysis patients is predicted by both patient and practice characteristics. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3581-3587.	0.4	75
46	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 903-914.	5.5	73
47	Cloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach. <i>Annals of Internal Medicine</i> , 2020, 173, 489-491.	2.0	68
48	Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 805-814.	2.2	65
49	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
50	A Trial of Extending Hemodialysis Hours and Quality of Life. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1898-1911.	3.0	62
51	Antiplatelet agents for chronic kidney disease. , 2013, , CD008834.		61
52	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
53	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.	1.0	60
54	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 1854-1867.	2.9	58

#	ARTICLE	IF	CITATIONS
55	Tripterygium Preparations for the Treatment of CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2013, 62, 515-530.	2.1	53
56	Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases, 2013, 61, 247-253.	2.1	52
57	Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease. JAMA Internal Medicine, 2019, 179, 1316.	2.6	52
58	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	3.0	52
59	Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion, 2015, 31, 2219-2231.	0.9	49
60	Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks – A Narrative Review. Mayo Clinic Proceedings, 2020, 95, 2204-2224.	1.4	46
61	Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney International, 2008, 73, 963-970.	2.6	40
62	<sc>Sodium-glucose cotransporter</sc> inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 382-390.	2.2	40
63	If you can't comply with dialysis, how do you expect me to trust you with transplantation? Australian nephrologists' views on indigenous Australians' 'non-compliance' and their suitability for kidney transplantation. International Journal for Equity in Health, 2012, 11, 21.	1.5	39
64	A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study. Blood Purification, 2020, 49, 468-478.	0.9	38
65	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases, 2021, 77, 23-34.e1.	2.1	38
66	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	2.2	37
67	Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter² inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes, Obesity and Metabolism, 2020, 22, 46-54.	2.2	36
68	Cyclosporine Withdrawal Improves Long-Term Graft Survival in Renal Transplantation. Transplantation, 2009, 87, 1877-1883.	0.5	35
69	Non-tuberculous mycobacterial PD peritonitis in Australia. International Urology and Nephrology, 2013, 45, 1423-1428.	0.6	33
70	Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. PLoS ONE, 2019, 14, e0213192.	1.1	32
71	Impact of Estimated GFR Reporting on Late Referral Rates and Practice Patterns for End-Stage Kidney Disease Patients: A Multilevel Logistic Regression Analysis Using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). American Journal of Kidney Diseases, 2014, 64, 359-366.	2.1	31
72	The effect of canagliflozin on amputation risk in the <sc>CANVAS</sc> program and the <sc>CREDENCE</sc> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1753-1766.	2.2	31

#	ARTICLE	IF	CITATIONS
73	Muscle strength, mobility, quality of life and falls in patients on maintenance haemodialysis: A prospective study. <i>Nephrology</i> , 2017, 22, 220-227.	0.7	30
74	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
75	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 49-57.	2.1	29
76	SGLT2 inhibitors may offer benefit beyond diabetes. <i>Nature Reviews Nephrology</i> , 2021, 17, 83-84.	4.1	29
77	The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. <i>Quality of Life Research</i> , 2019, 28, 2081-2090.	1.5	27
78	Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2875-2888.	0.4	26
79	Considerations of Nephrologists when Suggesting Dialysis in Elderly patients with Renal failure (CONSIDER): a discrete choice experiment. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2302-2309.	0.4	26
80	Health-related quality of life in survivors of acute kidney injury: The PROLONGED OUTCOMES STUDY of the Randomized Evaluation of Normol versus Augmented Level Replacement Therapy study outcomes. <i>Nephrology</i> , 2015, 20, 492-498.	0.7	26
81	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 265-278.	1.1	25
82	Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. <i>BMJ</i> , The, 2016, 355, i5599.	3.0	25
83	Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0184398.	1.1	25
84	Chemokine and toll-like receptor signaling in macrophage mediated islet xenograft rejection. <i>Xenotransplantation</i> , 2007, 14, 48-59.	1.6	23
85	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2022, 79, 244-256.e1.	2.1	23
86	Prediction of 10-year vascular risk in patients with diabetes: the ADA risk score. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 289-294.	2.2	21
87	Interventions for lowering plasma homocysteine levels in dialysis patients. <i>The Cochrane Library</i> , 2016, 2016, CD004683.	1.5	21
88	Photopheresis therapy for problematic renal allograft rejection. <i>Journal of Clinical Apheresis</i> , 2009, 24, 161-169.	0.7	19
89	Action plan for optimizing the design of clinical trials in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 138-144.	4.6	19
90	Effects of Hemodiafiltration and High Flux Hemodialysis on Nerve Excitability in End-Stage Kidney Disease. <i>PLoS ONE</i> , 2013, 8, e59055.	1.1	18

#	ARTICLE	IF	CITATIONS
91	Design and participant baseline characteristics of a multicenter trial of Intensive Dialysis™: The ACTIVE Dialysis Study. <i>Nephrology</i> , 2015, 20, 257-265.	0.7	18
92	Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. <i>The Cochrane Library</i> , 2016, 4, CD009631.	1.5	18
93	We Need to Talk about Depression and Dialysis: but What Questions Should We Ask, and Does Anyone Know the Answers?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 222-224.	2.2	18
94	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , 2020, 318, 126-129.	0.8	18
95	Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i48-i55.	0.4	18
96	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <i>Cmaj</i> , 2019, 191, E1128-E1135.	0.9	17
97	Angiotensin-converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of RENAL study outcomes. <i>Nephrology</i> , 2014, 19, 617-622.	0.7	16
98	Cardiovascular Outcomes Reported in Hemodialysis Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2802-2810.	1.2	16
99	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021, 8, 1482-1493.	1.4	16
100	Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study. <i>Diabetes Care</i> , 2020, 43, 982-990.	4.3	15
101	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	1.4	15
102	GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. <i>Kidney International</i> , 2022, 101, 360-368.	2.6	15
103	Closing the gap between evidence and practice in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 114-121.	4.6	14
104	Identifying and integrating patient and caregiver perspectives for clinical practice guidelines on the screening and management of infectious microorganisms in hemodialysis units. <i>Hemodialysis International</i> , 2017, 21, 213-223.	0.4	13
105	Varying Association of Extended Hours Dialysis with Quality of Life. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1751-1762.	2.2	13
106	mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 242-244.	0.4	12
107	Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 87.	0.7	12
108	Quality of life in caregivers compared with dialysis recipients: The CoACTIVE sub-study of the ACTIVE dialysis trial. <i>Nephrology</i> , 2019, 24, 1056-1063.	0.7	12

#	ARTICLE	IF	CITATIONS
109	The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 763-773.	2.2	12
110	Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 252-257.	2.2	12
111	Design and methods of the REMOVAL-HD study: a trial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in Haemodialysis patients. <i>BMC Nephrology</i> , 2018, 19, 89.	0.8	11
112	Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial. , 2019, 29, 276-284.		11
113	Renal, cardiovascular and safety outcomes of canagliflozin in patients with type-2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial. <i>Journal of Diabetes Investigation</i> , 2022, 13, 54-64.	1.1	11
114	Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-36 utility and mental component SF-36 quality of life: An AusDiab analysis. <i>Nephrology</i> , 2019, 24, 605-614.	0.7	10
115	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	2.1	10
116	Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. <i>Hemodialysis International</i> , 2021, 25, 322-332.	0.4	10
117	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1365-1375.	2.2	10
118	<i>Mycobacterium fortuitum</i> as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature. <i>BMC Nephrology</i> , 2012, 13, 35.	0.8	9
119	Renal trials in diabetes need a platform: time for a global approach?. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 356-358.	5.5	9
120	Examining Outcomes in Chronic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e15646.	0.5	9
121	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDESCENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	2.2	9
122	SGLT2 inhibitors and finerenone: one or the other or both?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1209-1211.	0.4	9
123	Scoring Risk Scores: Considerations Before Incorporating Clinical Risk Prediction Tools Into Your Practice. <i>American Journal of Kidney Diseases</i> , 2017, 69, 555-557.	2.1	8
124	Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. <i>BMJ Open</i> , 2019, 9, e023736.	0.8	8
125	Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis. <i>Journal of Cardiac Failure</i> , 2020, 26, 482-491.	0.7	8
126	Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. <i>Kidney International Reports</i> , 2021, 6, 284-295.	0.4	8

#	ARTICLE	IF	CITATIONS
127	Benefits of exercise training in patients receiving haemodialysis: a systematic review and meta-analysis. <i>British Journal of Sports Medicine</i> , 2011, 45, 1165-1166.	3.1	7
128	Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. <i>BMC Nephrology</i> , 2019, 20, 258.	0.8	7
129	Cardiovascular adaptations associated with exercise in patients on hemodialysis. <i>Seminars in Dialysis</i> , 2019, 32, 361-367.	0.7	7
130	Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review. <i>BMJ Global Health</i> , 2019, 4, e001940.	2.0	7
131	Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811989439.	0.6	7
132	Effect of extended hours dialysis on sleep quality in a randomized trial. <i>Nephrology</i> , 2019, 24, 430-437.	0.7	7
133	Protocol for the Controlled evaluation of Angiotensin Receptor blockers for COVID-19 respiratory disease (CLARITY): a randomised controlled trial. <i>Trials</i> , 2021, 22, 573.	0.7	7
134	Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities. <i>American Journal of Kidney Diseases</i> , 2019, 74, 659-666.	2.1	6
135	Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 22, 100240.	1.0	6
136	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.	0.8	6
137	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	2.2	6
138	Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2707-2715.	2.2	6
139	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021, 64, 2402-2414.	2.9	6
140	Antiplatelet agents for chronic kidney disease. <i>The Cochrane Library</i> , 2022, 2022, CD008834.	1.5	6
141	Effect of a Vascular Access Surveillance Program on Service Provision and Access Thrombosis. <i>Seminars in Dialysis</i> , 2013, 26, 361-365.	0.7	5
142	Kidney Health Australia – Caring for Australasians with Renal Impairment guideline recommendations for infection control for haemodialysis units. <i>Nephrology</i> , 2019, 24, 951-957.	0.7	5
143	Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1129-1138.	2.2	5
144	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1761-1769.	0.4	5

#	ARTICLE	IF	CITATIONS
145	Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00247.	1.0	5
146	Sex differences in chronic kidney disease prevalence in Asia: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1144-1151.	1.4	5
147	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	1.4	5
148	Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812210803.	0.6	5
149	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. <i>Kidney International</i> , 2021, 99, 519-523.	2.6	4
150	SGLT2 inhibitors may prevent diabetes. <i>Nature Reviews Nephrology</i> , 2022, 18, 203-204.	4.1	4
151	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 665-673.	3.0	4
152	Interventions for lowering plasma homocysteine levels in kidney transplant recipients. <i>The Cochrane Library</i> , 2015, 2015, CD007910.	1.5	3
153	Impact of supplemental private health insurance on dialysis and outcomes. <i>Internal Medicine Journal</i> , 2020, 50, 542-549.	0.5	3
154	No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial. <i>Nephrology</i> , 2020, 25, 792-800.	0.7	3
155	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the <scp>ADVANCE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1420-1425.	2.2	3
156	Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 1058-1065.	0.4	3
157	1130-P: Temporal Trends in Pharmacotherapy for Diabetes. <i>Diabetes</i> , 2019, 68, 1130-P.	0.3	3
158	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	1.0	3
159	Comparative efficacy of a team-led treatment protocol for the management of renal anaemia. <i>Nephrology</i> , 2013, 18, 649-654.	0.7	2
160	First Light After the Long Night: A Follow-up Report of the Randomized FHN Nocturnal Trial. <i>American Journal of Kidney Diseases</i> , 2015, 66, 379-382.	2.1	2
161	Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE. <i>Journal of Nephrology</i> , 2020, 33, 977-983.	0.9	2
162	EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL. <i>Journal of the American College of Cardiology</i> , 2020, 75, 215.	1.2	2

#	ARTICLE	IF	CITATIONS
163	Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide. <i>Nephrology</i> , 2021, 26, 12-14.	0.7	2
164	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. <i>Kidney International</i> , 2021, 99, 551-554.	2.6	2
165	27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Diabetes</i> , 2020, 69, .	0.3	2
166	Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3127-3127.	0.4	1
167	How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 823-836.	0.9	1
168	Therapy Escalation Following an Elevated HbA1c in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. <i>Diabetes Care</i> , 2020, 43, e185-e187.	4.3	1
169	EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION. <i>Journal of the American College of Cardiology</i> , 2020, 75, 221.	1.2	1
170	Cloth Masks May Prevent Transmission of COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 580.	2.0	1
171	Prior Cardiovascular Treatmentsâ€™ A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction. <i>Frontiers in Pharmacology</i> , 2022, 13, 834898.	1.6	1
172	Obstructive nephropathy secondary to a massive vesical calculus. <i>Internal Medicine Journal</i> , 2012, 42, 471-472.	0.5	0
173	Glucose lowering and the kidney: are all drug classes equal?. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 835-837.	5.5	0
174	Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning. <i>Journal of Cardiac Failure</i> , 2020, 26, 1028-1029.	0.7	0
175	Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154509.	1.5	0
176	129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial. <i>Diabetes</i> , 2021, 70, 129-LB.	0.3	0
177	133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE. <i>Diabetes</i> , 2021, 70, 133-LB.	0.3	0
178	131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial. <i>Diabetes</i> , 2021, 70, 131-LB.	0.3	0
179	Acute Dialysis in Older Patients. , 2014, , 59-71.		0
180	Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease. <i>Diabetes</i> , 2018, 67, 258-OR.	0.3	0

#	ARTICLE	IF	CITATIONS
181	1129-P: Association between the Intensity of Diabetes Therapy, Achieved HbA1c, and Persistence. Diabetes, 2019, 68, .	0.3	0
182	1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial. Diabetes, 2020, 69, .	0.3	0
183	1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD). Diabetes, 2020, 69, .	0.3	0
184	26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE. Diabetes, 2020, 69, .	0.3	0
185	Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review. CKJ: Clinical Kidney Journal, 0, , .	1.4	0
186	A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation. Frontiers in Cardiovascular Medicine, 2022, 9, 840611.	1.1	0